respiratori
syncyti
viru
rsv
viru
commonli
associ
bronchiol
affect
infant
young
rsv
induc
lower
respiratori
tract
ill
lrti
encompass
bronchiol
viral
pneumonia
lead
death
sever
children
infect
rsv
age
year
nearli
half
case
experi
recurr
larg
proport
young
patient
rsv
bronchiol
recurr
episod
lower
airway
obstruct
may
continu
year
acut
infect
sever
prospect
birth
cohort
studi
report
lrti
play
import
caus
role
pathogenesi
recurr
wheez
howev
current
therapeut
option
limit
support
treatment
focus
fluid
respiratori
mainten
need
wide
avail
prevent
addit
mechan
rsv
evad
host
defens
fulli
clarifi
rsv
pathogenesi
human
develop
prophylact
therapeut
strategi
rsv
infect
respiratori
tract
requir
recent
chitinas
protein
human
breast
regress
protein
brp
mice
implic
develop
asthma
circul
level
increas
patient
asthma
correl
diseas
variant
affect
serum
level
influenc
asthma
statu
lung
identifi
import
regul
allerg
respons
tissu
remodel
also
link
type
chronic
lung
inflamm
acut
lung
howev
role
viral
respiratori
infect
previous
investig
studi
hypothes
involv
airway
inflamm
induc
rsv
infect
investig
possibl
measur
human
nasopharyng
aspir
npa
hospit
children
present
acut
respiratori
symptom
compar
immun
respons
induc
rsv
wt
knockout
ko
mice
found
rsv
infect
induc
immun
respons
murin
model
may
enhanc
airway
hyperrespons
ahr
inflammatori
cell
recruit
mucu
product
mice
moreov
treatment
antibodi
attenu
airway
inflamm
cytokin
product
wt
mice
suggest
therapeut
candid
treatment
lrti
decemb
februari
nasopharyng
aspir
collect
children
hospit
sever
children
hospit
due
acut
respiratori
symptom
cough
wheez
tachypnea
npa
collect
steril
suction
cathet
insert
oropharynx
nostril
gentl
suction
appli
use
electr
suction
wash
cathet
normal
salin
sampl
place
viral
transport
medium
kept
process
npa
test
multiplex
viru
pcr
panel
includ
rsv
ab
hrv
abc
adenoviru
bocaviru
coronaviru
parainfluenza
viru
influenza
viru
ab
metapneumoviru
mycoplasma
antibodi
serum
bacteri
cultur
blood
npa
also
evalu
children
congenit
heart
diseas
chronic
lung
diseas
associ
prematur
recurr
infect
histori
prematur
exclud
patient
respiratori
infect
detect
use
multiplex
viru
pcr
panel
serolog
test
also
exclud
children
ultim
enrol
studi
children
belong
group
rsv
infect
establish
npa
control
group
includ
patient
mild
respiratori
symptom
pathogen
detect
evalu
sever
respiratori
ill
respiratori
symptom
score
time
level
npa
measur
use
immunosorb
assay
elisa
kit
r
system
minneapoli
mn
usa
studi
approv
institut
review
board
sever
hospit
seoul
korea
studi
particip
provid
inform
consent
procedur
carri
accord
relev
guidelin
regul
rsv
strain
propag
cell
american
type
cultur
collect
manassa
va
usa
harvest
day
postinfect
dpi
cytopath
effect
infect
cell
maxim
final
titer
also
establish
cell
determin
standard
plaqu
wt
mice
seoul
korea
null
anesthet
inocul
via
intratrach
rout
unit
rsv
equal
volum
pb
mock
inoculum
figur
sever
ill
evalu
daili
base
weight
loss
anim
hous
specif
condit
experi
approv
conduct
guidelin
institut
anim
care
use
committe
yonsei
univers
colleg
medicin
seoul
korea
bronchoalveolar
lavag
fluid
balf
specimen
harvest
dpi
lung
resist
measur
dpi
previous
section
lung
specimen
stain
hematoxylin
eosin
h
e
period
pa
assess
inflamm
mucu
product
respect
express
detect
ihc
use
human
cartilag
antibodi
santa
cruz
biotechnolog
dalla
tx
usa
identifi
alveolar
macrophag
produc
antibodi
ebiosci
san
diego
ca
usa
santa
cruz
use
level
balf
measur
use
cytokin
bead
array
cba
flexset
kit
bd
pharmingen
san
diego
ca
usa
accord
manufactur
instruct
level
balf
lung
lysat
measur
use
elisa
kit
r
system
direct
manufactur
protein
measur
elisa
previous
describ
lee
et
taqman
set
gapdh
purchas
appli
biosystem
foster
citi
ca
usa
rel
mrna
level
determin
compar
method
rsv
quantif
known
concentr
rsv
use
gener
standard
curv
standard
neg
control
includ
pcr
assay
custom
taqman
set
rsv
n
gene
region
rsv
gene
express
quantifi
use
stepon
pcr
system
appli
biosystem
whole
lung
mous
prepar
follow
previous
isol
cell
incub
fc
block
antibodi
bd
pharmingen
stain
rat
bd
pharmingen
rat
bd
pharmingen
ebiosci
biolegend
bd
bioscienc
franklin
lake
nj
usa
alexa
fluor
hamster
bd
bioscienc
rat
bd
pharmingen
bronchoalveolar
lavag
fluid
cell
collect
stimul
hour
ngml
ionomycin
presenc
protein
transport
inhibitor
cell
label
protein
fixedpermeabil
incub
antibodi
ebiosci
sampl
analyz
lsr
ii
flow
cytomet
bd
bioscienc
use
flowjo
softwar
tree
star
ashland
usa
assess
altern
macrophag
activ
alveolar
macrophag
balf
lung
cell
examin
surfac
express
arginas
activ
balf
lung
lysat
measur
use
quantichrom
arginas
assay
kit
bioassay
system
hayward
ca
usa
accord
manufactur
wt
mice
administ
singl
dose
antibodi
r
system
vehicl
via
intraperiton
rout
hour
rsv
infect
mice
euthan
dpi
inflamm
immun
respons
induc
rsv
infect
analyz
chang
express
also
note
lung
harvest
group
stain
h
e
pa
evalu
inflamm
mucu
product
respect
baselin
characterist
patient
compar
u
test
fisher
exact
test
appropri
correl
level
npa
determin
spearman
rank
correl
test
data
analyz
spss
softwar
spss
inc
chicago
il
usa
experiment
data
express
mean
sd
group
compar
unpair
student
test
anova
bonferroni
correct
appropri
use
prism
softwar
graphpad
inc
la
jolla
ca
usa
p
consid
statist
signific
investig
relationship
rsv
infect
level
npa
sampl
hospit
children
measur
figur
clinic
characterist
subject
summar
intabl
patient
rsv
infect
patient
without
confirm
pathogen
signific
differ
age
gender
durat
admiss
past
histori
laboratori
find
children
confirm
rsv
infect
show
higher
score
acut
respiratori
symptom
time
admiss
control
group
p
children
rsv
infect
higher
figur
figur
level
control
subject
patient
rsv
infect
level
posit
correl
symptom
score
figur
level
npa
figur
data
suggest
express
increas
rsv
infect
correl
sever
symptom
children
moreov
express
may
relat
express
airway
inflamm
compar
express
control
mice
dpi
children
rsv
infect
level
lung
balf
increas
compar
control
mice
figur
induct
promin
airway
epitheli
cell
figur
alveolar
macrophag
figur
wt
mice
rsv
infect
caus
inflammatori
chang
weight
loss
increas
ahr
methacholin
challeng
test
well
increas
inflammatori
cell
recruit
balf
dpi
figur
total
cell
count
neutrophil
lymphocyt
eosinophil
count
increas
rsv
infect
figur
induct
inflamm
less
sever
infect
ko
mice
rather
wt
rsv
mice
figur
histolog
analysi
reveal
tissu
inflamm
figur
mucu
product
figur
f
also
decreas
null
mice
differ
viral
load
rsv
infect
wt
ko
mice
figur
data
indic
loss
could
attenu
airway
inflamm
induc
rsv
infect
without
signific
chang
viral
load
given
inflamm
major
consequ
rsv
infect
hypothes
might
affect
inflamm
defici
decreas
airway
inflamm
mice
compar
cell
recruit
lung
rsv
infect
increas
number
cell
dendrit
cell
dc
eosinophil
seen
wt
ko
mice
figur
rsv
infect
caus
signific
increas
cytokin
mrna
level
lung
wt
mice
level
increas
fold
compar
level
wt
pb
group
addit
lung
mrna
express
strikingli
increas
fold
wt
mice
contrast
cytokin
mrna
level
significantli
alter
infect
ko
mice
figur
unlik
cytokin
level
balf
increas
wt
mice
upon
rsv
infect
undetect
ko
mice
figur
also
observ
increas
number
cell
wt
ko
mice
infect
rsv
figur
case
inflammatori
cytokin
rsv
infect
caus
upregul
level
wt
ko
mice
figur
wherea
level
chang
group
data
shown
thu
could
exacerb
inflamm
especi
express
mice
effect
product
inflammatori
cytokin
next
investig
mechan
drive
inflamm
ahr
rsv
infect
mice
sinc
altern
activ
macrophag
known
affect
inflamm
rsv
infect
associ
allerg
inflamm
evalu
macrophag
activ
found
number
macrophag
balf
lung
cell
increas
infect
mice
figur
c
moreov
macrophag
arginas
activ
balf
figur
lung
lysat
figur
increas
infect
wt
ko
mice
although
lower
latter
result
indic
regul
accumul
activ
macrophag
induc
inflamm
rsv
infect
consist
data
decreas
airway
inflamm
null
mice
evalu
therapeut
effect
antibodi
rsv
infect
found
singl
dose
antibodi
administ
wt
mice
intraperiton
inject
hour
rsv
infect
decreas
inflammatori
respons
figur
well
express
figur
f
rel
wt
rsv
mice
histolog
examin
reveal
inflamm
figur
mucu
product
figur
also
decreas
antibodi
treatment
effect
viral
load
lung
figur
cytokin
level
also
decreas
mice
treat
antibodi
compar
control
group
show
greatest
reduct
figur
collect
result
indic
attenu
immunopatholog
rsv
infect
studi
investig
relationship
rsv
infect
children
murin
model
found
mous
requir
sever
lung
immunopatholog
caus
rsv
infect
sinc
mice
show
reduc
weight
loss
ahr
inflammatori
cell
infiltr
airway
mucu
product
despit
similar
viral
load
wt
mice
thu
could
potenti
therapeut
target
immunopatholog
associ
rsv
infect
moreov
vivo
neutral
use
antibodi
could
decreas
sever
airway
inflamm
rsv
infect
protein
clp
structur
similar
chitinas
lack
enzymat
activ
recent
studi
shown
mammalian
clp
present
site
inflamm
tissu
remodel
trigger
immun
respons
attract
eosinophil
cell
even
case
parasit
allerg
respons
key
regul
inflamm
macrophag
differenti
cell
macrophag
apoptosiscel
death
null
mice
show
signific
defect
inflamm
inflamm
human
relationship
asthma
develop
also
known
bind
compos
multimer
complex
mechan
mediat
downstream
effect
poorli
understood
studi
investig
relationship
viral
respiratori
infect
induc
inflamm
asthma
respiratori
syncyti
viru
known
major
caus
sever
lrti
infant
young
caus
agent
pathogenesi
recurr
wheez
possibl
relationship
exist
rsv
lrti
asthma
unclear
whether
rsv
risk
factor
marker
predisposit
asthma
identifi
molecul
involv
pathway
provid
basi
prevent
asthma
develop
respiratori
syncyti
viru
infect
airway
epitheli
cell
pulmonari
macrophag
lead
upregul
cytokin
chemokin
rant
inflammatori
cell
recruit
lung
classic
cell
known
associ
advanc
airway
inflamm
rsv
thought
relat
develop
wheez
asthma
skew
immun
system
away
antivir
respons
toward
cytokin
could
contribut
enhanc
lung
damag
increas
ahr
eosinophil
chemotaxi
mucu
macrophag
induc
also
known
gener
rsv
infect
caus
immun
respons
lead
develop
recent
studi
report
cytokin
thymic
stromal
lymphopoietin
tslp
could
induc
group
innat
lymphoid
cell
prolifer
howev
contribut
pathophysiolog
sever
rsv
infect
remain
unclear
investig
relationship
lrti
use
null
mice
product
airway
increas
follow
rsv
infect
airway
inflamm
diminish
absenc
respons
increas
dc
macrophag
observ
decreas
inflamm
rsv
infect
may
due
decreas
popul
dc
macrophag
sinc
dc
consid
major
cell
rsv
infect
matur
antigen
recognit
capac
could
alter
cytokin
milieu
varieti
macrophag
known
critic
regul
immun
respons
sever
acut
viral
infect
via
differenti
activ
macrophag
consid
contributor
product
posit
feedback
thu
defici
could
alter
progress
inflamm
induc
rsv
infect
without
affect
viru
interestingli
antibodi
treatment
hour
rsv
infect
attenu
airway
inflamm
product
cytokin
especi
result
suggest
requir
airway
inflamm
could
serv
potenti
therapeut
target
treatment
lrti
although
precis
mechan
investig
studi
predict
regul
inflamm
involv
signal
vitro
studi
found
bronchial
epitheli
cell
treat
show
increas
product
depend
mapk
jnk
erk
pathway
activ
stimul
prolifer
migrat
bronchial
smooth
muscl
moreov
product
found
enhanc
via
activ
signal
rsv
studi
focus
inflamm
adapt
immun
phase
relationship
airway
epithelium
immun
respons
earli
stage
infect
investig
sinc
immunopatholog
earli
phase
rsv
infect
explain
posit
feedback
loop
cytokin
might
possibl
enhanc
inflamm
rsv
infect
uniqu
cytokin
could
stimul
proven
also
potent
stimul
fibrot
product
could
also
induc
rsv
rsv
infect
increas
could
thought
stimul
epitheli
cell
produc
enhanc
inflamm
addit
express
receptor
effector
investig
studi
examin
innat
immun
respons
eg
cytokin
earli
phase
rsv
infect
null
mice
well
express
regul
rsv
infect
need
better
understand
relationship
rsv
infect
neonat
model
rsv
infect
null
mice
may
also
use
investig
role
asthma
develop
would
consist
role
viral
bronchiol
asthma
incept
conclus
studi
confirm
express
significantli
increas
human
npa
children
lrti
use
ko
mice
demonstr
import
regul
airway
inflamm
rsv
infect
induc
upregul
produc
macrophag
epitheli
cell
site
inflamm
defici
attenu
weight
loss
ahr
respons
well
increas
dc
macrophag
activ
addit
airway
inflamm
product
decreas
antibodi
treatment
data
suggest
play
import
role
airway
inflamm
neutral
potenti
therapeut
strategi
treatment
lrti
author
declar
conflict
interest
mj
kim
dh
shim
contribut
studi
design
perform
experi
analyz
data
draft
manuscript
hr
cha
ky
moon
cm
yang
sj
hwang
perform
experi
analyz
data
kw
kim
jh
park
supervis
studi
perform
experi
interpret
data
draft
manuscript
cg
lee
ja
elia
gener
null
mice
mh
sohn
jm
lee
author
approv
final
version
manuscript
take
respons
manuscript
content
